Skip to main content

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Completed · Phase 3 · NCT04136171

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

At a glance

Research payments reported, 2025
$2.8M
U.S. investigators named
45
Sites paid
46
Planned or actual enrollment
1,438

About the trial

Sponsor
Ionis Pharmaceuticals, Inc. (with AstraZeneca)
Tested
Eplontersen (drug), Placebo (drug)
Dates
Started 2020-03-13; completion 2026-08-12
Results posted
Not yet

To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC).

From ClinicalTrials.gov, last updated 2026-09-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ionis Pharmaceuticals, Inc. reported $2.8M in research payments for this study in 2025 (328 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.